The serine/threonine kinase WNK3 and the ubiquitin-protein ligase NEDD4-2 are key regulators of the thiazide-sensitive Na ϩ -Cl Ϫ cotransporter (NCC), WNK3 as an activator and NEDD2-4 as an inhibitor. Nedd4-2 was identified as an interacting partner of WNK3 through a glutathione-S-transferase pull-down assay using the N-terminal domain of WNK3, combined with LC-MS/MS analysis. This was validated by coimmunoprecipitation of WNK3 and NEDD4-2 expressed in HEK293 cells. Our data also revealed that the interaction between Nedd4-2 and WNK3 does not involve the PY-like motif found in WNK3. The level of WNK3 ubiquitylation did not change when NEDD4-2 was expressed in HEK293 cells. Moreover, in contrast to SGK1, WNK3 did not phosphorylate NEDD4-2 on S222 or S328. Coimmunoprecipitation assays showed that WNK3 does not regulate the interaction between NCC and NEDD4-2. Interestingly, in Xenopus laevis oocytes, WNK3 was able to recover the SGK1-resistant NEDD4-2 S222A/S328A-mediated inhibition of NCC and further activate NCC. Furthermore, elimination of the SPAK binding site in the kinase domain of WNK3 (WNK3-F242A, which lacks the capacity to bind the serine/threonine kinase SPAK) prevented the WNK3 NCC-activating effect, but not the Nedd4-2-inhibitory effect. Together, these results suggest that a novel role for WNK3 on NCC expression at the plasma membrane, an effect apparently independent of the SPAK kinase and the aldosterone-SGK1 pathway.
WNK; ubiquitylation; salt transport; distal convoluted tubule; hypertension THE RENAL NA ϩ -CL Ϫ COTRANSPORTER (NCC) is the major salt transport pathway in the distal convoluted tubule (DCT) of the nephron and plays an important role in the regulation of arterial blood pressure and renal handling of salt, potassium and pH. NCC is the target of thiazide-type diuretics that are extensively used for the treatment of arterial hypertension. The activity of NCC is subject to a complex regulatory network, including aldosterone (1, 28, 72) , angiotensin II (56, 58, 71) , norepinephrine (39) , and vasopressin (40, 46) . The molecular mechanisms, through which NCC is regulated, and in particular the increasingly important role that the With No lysine (K) (WNK) kinases play in its regulation have come to the forefront in recent years, after mutations in the PRKWNK1 or PRKWNK4 genes were found to be responsible for pseudohypoaldosteronism type II (PHAII; also known as familial hyperkalemic hypertension, FHHt, or Gordon syndrome) (75) , an autosomal dominant disease characterized by hyperkalemia, metabolic acidosis, and arterial hypertension (20) , which is corrected with low-dose thiazide treatment (21, 33) . Interestingly, PHAII is the mirror image of Gitelman disease, an autosomal recessive disease featuring hypokalemia, metabolic alkalosis, and hypotension (62) , which is due to inactivating mutations of the SLC12A3 gene encoding NCC.
The particular role that WNK kinases play in the regulation of NCC is highlighted by the observation that an increase in NCC total protein is not enough to recapitulate the PHAII phenotype (35, 54) , suggesting that an increase in the intrinsic activity of NCC is necessary. In vitro and in vivo models have shed light on the roles of the different members of the WNK kinase family in the regulation of NCC (16) . Wild-type WNK4 has been suggested to be an inhibitor of NCC in the absence of ANG II (53) . In contrast, in the presence of ANG II and STE/SPS1-related proline/alanine rich kinase (SPAK) or oxidative stress-responsive kinase 1 (OSR1), which lie downstream of WNKs, or when WNK4's primary structure is modified by PHAII-type mutations, WNK4 does not only lose the ability to inhibit NCC, but becomes an activator (26, 30, 56, 76) . In addition to the WNK-signaling cascade, the role of aldosterone in the regulation of NCC has also garnered attention in past years. In this context, we have recently shown that the aldosterone-SGK1-NEDD4-2 pathway, known to regulate the expression and activity of the epithelial Na ϩ channel (ENaC), also regulates NCC expression (3, 54) . Moreover, ubiquitylation defects have been suggested to be implicated in the development of PHAII due to mutations in the RING-type ubiquitin-protein ligase complex composed of CUL3 and KLHL3 proteins (7, 15, 32) . Recent reports show that CUL3 and KLHL3 proteins are regulators of WNK kinases (42, 60, 77) .
The effect of WNK1 (22, 36, 73) , the non-disease-causing WNK2 (52) , and WNK3 on the electroneutral cation-coupled chloride cotransporter has also been explored. WNK3 is a powerful in vitro activator of the NCC and bumetanide-sensitive Na
Ϫ cotransporters, NKCC1 and NKCC2 (25, 48, 51) , and an inhibitor of the K ϩ -Cl Ϫ cotransporters (11) . In addition, WNK3 has been reported to be an inhibitor of ROMK (31) . The combination of being an activator of NCC and an inhibitor of ROMK (31) in the distal convoluted tubule makes WNK3 an ideal regulatory kinase for the response to hypovolemia, in which salt reabsorption must be increased, while minimizing potassium secretion (4) . However, the in vivo role of WNK3 is less well established. Recently, two groups generated WNK3 knockout mice that exhibited a mild phenotype consisting of a small, but significant reduction in blood pressure during a low-salt diet (36, 43) , suggesting that WNK3 may play a minor role in NCC regulation. However, in both studies a compensatory increase in WNK1 expression was reported. Thus further studies, such as a conditional and/or kidneyspecific knockout model less prone to compensation, will be important to clarify the physiological role of WNK3.
We present evidence here of an additional pathway in NCC regulation by WNK3 (43) . WNK3 prevents the NEDD4-2-mediated inhibitory effect on NCC. This WNK3 effect is independent of both the activation of NCC by the WNK3-SPAK pathway and the SGK1-mediated phosphorylation of NEDD4-2 on S222 and S328, suggesting a novel role for WNK3 on NCC expression at the plasma membrane, an effect apparently independent of the aldosterone-SGK1 pathway.
MATERIALS AND METHODS

Xenopus Laevis Experiments
cDNA constructs. The Flag-tagged rat NCC, mouse NEDD4-2, the NEDD4-2 mutant in which serine residues 222 and 328 were substituted by alanine, c-Myc-tagged human WNK3, WNK3-F242A, and HA-tagged mouse WNK4 used for the present study have been previously reported (3, 38, 45, 51, 65, 76) . For cRNA synthesis, all cDNAs were linearized after the 3=-end untranslated region and in vitro cRNA transcription were carried out with an mMessage mMachine Kit (Ambion).
X. laevis oocyte preparation. Female X. laevis frogs were anesthetized with 0.17% Tricaine, and oocytes were harvested and placed in a frog Ca 2ϩ -free ND-96 solution (in mM: 96 NaCl, 2 KCl, 1 MgCl2, and 5 HEPES/Tris, pH 7.4) in the presence of type B collagenase for 1.5 h. Oocytes were then washed four times with an ND-96 solution (in mM: 96 NaCl, 2 KCl, 1.8 CaCl 2, 1 MgCl2, and 5 HEPES/Tris, pH 7.4) and stored overnight at 18°C in ND-96ϩ5 mg/100 ml gentamicin. After 24 h, oocytes were injected with 50 nl of H2O alone or containing 0.2-0.8 g/l of cRNA. Oocytes where then incubated for 48 -72 h at 18°C with daily changes of the ND-96ϩgentamicin medium. All X. laevis experiments were approved and performed following the guidelines set by the Institutional Animal Care Committee of our institution.
Transport assays. Function of the NCC was assessed following our protocol (37) of radioactive tracer ( 22 Na ϩ ; PerkinElmer Life Sciences) uptake. One hour before the beginning of the experiment, the oocytes were placed in a Cl Ϫ -free ND-96 solution (in mM: 96 Na ϩ isothionate, 2 K ϩ gluconate, 1.8 Ca 2ϩ gluconate, 1 Mg 2ϩ gluconate, and 5 HEPES, and 5 mg/100 ml gentamicin, pH 7.4). Oocytes were then placed in groups of 10 -15/well in Cl Ϫ -free ND-96 medium that contained 1 mM ouabain, 100 M amiloride, and 100 M bumetanide, in the presence or absence of 100 M metolazone. After 30 min in the preuptake medium, oocytes were placed in a K ϩ -free uptake medium (in mM: 40 NaCl, 56 sodium-gluconate, 4 CaCl2, 1 MgCl2, and 5 HEPES/Tris, pH 7.4) containing ouabain, amiloride, and bumetanide, with 1 Ci 22 Na ϩ per milliliter per well for 60 min at 32°C. Following uptake, oocytes were placed in ice-cold radioactive-free uptake medium and washed five times to remove any excess of tracer from oocyte membranes, and then placed in individual tubes and lysed with 1% NaOH solution for tracer activity determination with the use of ␤-scintillation counting.
Cell surface biotinylation of X. laevis oocytes. As described previously (3, 81) , oocytes were injected with cRNAs encoding NCC with or without wild-type NEDD4-2 and wild-type WNK3, and/or mutant WNK3-F242A cRNA, and washed five times in an ND-96 TEA buffer (in mM: 96 NaCl, 2 KCl, 1.8 CaCl 2, 1 MgCl2, 5 HEPES, pH 8.8, and 10 TEA) and incubated for 30 min with 1.5 mg/ml Sulfo-NHS-LCBiotin (Thermo; Pierce) in ice-cold ND-96-TEA. Oocytes were then washed five times in ND-96-TEA buffer and homogenized using a 25-gauge needle in a sucrose-based buffer (5 l/oocyte) comprising 250 mM sucrose, 0.5 mM EDTA, 5 mM Tris·HCl, pH 6.9, 1 mM phenylmethylsulfonyl fluoride (PMSF), and 10 l/ml protease inhibitor cocktail (P8340; Sigma, St. Louis, MO). Samples were centrifuged for 7 min at 8,000 rpm, the supernatant was collected, and protein concentration was assessed utilizing a Bradford assay (BioRad Reagents). Streptavidin precipitation was carried out by adding 75 l of streptavidin-agarose beads in 50% slurry (cell signaling solutions, Upstate) to 400 g of biotinylated total protein diluted in 1 ml of Tris-buffered saline (100 mM NaCl, 50 mM Tris·HCl, pH 7.4). Samples were rolled overnight at 4°C. The beads were then washed one time with buffer A (in mM: 5 EDTA, 50 NaCl, 50 Tris·HCl, pH 7.4), twice with buffer B (500 mM NaCl, 20 mM Tris·HCl, pH 7.4), and once with buffer C (10 mM Tris·HCl, pH 7.4) with a 2-min, 5,000-g spin between each wash. After the last wash, buffer C was substituted with 30 l of Laemmli sample buffer with 5% 2-mercaptoethanol (Sigma, Bio-Rad). Protein samples were heated to 65°C for 15 min before separation on a 7.5% polyacrylamide gel.
Western blotting of X. laevis oocyte proteins. Flag-tagged NCC protein was revealed using a commercial Flag antibody (Sigma). Protein membranes were placed in the Snap id vacuum (Millipore) and exposed to a 0.25% dry milk blocking solution for 15 min, after which they were exposed to a 1:2,500 Flag antibody solution and then washed four times with TBS-Tween 0.2% solution. Membranes were then incubated with the secondary antibody coupled to horseradish peroxidase (HRP), washed, sprayed with Luminata Classic Western HRP Substrate (Merck-Millipore), and developed.
mpkDCT Cell Experiments cDNA constructs. WNK3 and WNK4 constructs are described elsewhere (51, 76) . N-terminal regions of WNK3 (aa 1-146) and WNK4 (aa 1-173) (57) were subcloned into pGEX4T1.
mpkDCT cell culture. mpkDCT cells were kindly provided by Dr. A. Vanderwalle (Institut National de la Santé et de la Recherche Médicale, INSERM, Unité 478, Paris, France) and cultured as described previously (12) .
Glutathione-S-transferase fusion protein (production and purification). pGEX4T1 constructs were integrated in Escherichia coli BL21-competent cells. Bacteria were inoculated on LB-AMP plates overnight at 37°C. For each construct, a single colony was inoculated in 25 ml of LB-AMP culture and incubated at 37°C overnight. For each construct, 500 ml of LB-AMP culture was inoculated with the overnight 25-ml culture. These cultures were grown at 37°C until OD 0.5-0.6, then IPTG (1 mM final) was added, and flasks were incubated for 3 h at 30°C. Then, the competent cells were centrifuged 15 min at 4,000 g at 4°C. The pellets were kept and resuspended in 20 ml sonication buffer (50 mM Tris, pH 8.0, 50 mM NaCl, 1 mM EDTA). , and 2 ml of Triton X-100 (10%) were added. The suspensions were sonicated on ice using a probe-tip sonicator for 1 min, setting 7 and centrifuged at 27,000 g for 15 min at 4°C. The supernatants containing the soluble fusion protein were kept. Then, 1.5 ml of glutathione agarose (Sigma) was incubated with 25 ml of the supernatants containing soluble proteins. The glutathione agarose was washed two times with 25 ml of NETN (0.5% NP-40, 20 mM Tris, pH 8.0, 100 mM NaCl, 1 mM EDTA) (66) .
Pull-down experiments. mpkDCT cells were washed twice with cold PBS (1ϫ) and lysed in 1 ml of lysis buffer (50 mM HEPES, 150 mM NaCl, 1.5 mM MgCl2, 1 mM EGTA, 10% glycerol and 1% Triton X-100) containing protease inhibitors [10 m PMSF, 10 m aprotinin, 10 m leupeptin, 10 m pepstatin, 0.2 mM N-ethylmaleim-ide (Fluka, Buchs, Switzerland), and 1 mM dithiothreitol (Sigma)] and phosphatase inhibitors (100 mM NaF and 10 mM Na-pyrophosphate) in a 1.5-ml falcon. Lysates were kept 1 h on a wheel at 4°C and then centrifuged for 15 min at 20,000 g at 4°C. Protein concentration in supernatants was quantified using the Bradford method. Pull down was performed with 30 mg of protein. Diluted lysates were incubated overnight at 4°C with glutathione agarose containing glutathione-Stransferase (GST)-Nter WNK3, GST-Nter WNK4, or GST alone. The samples were centrifuged and washed four times with 1 ml of washing buffer (50 mM HEPES, pH 7.4, 150 mM NaCl, 1 mM EGTA, 10% glycerol, 0.2% Triton X-100, and 1.5 mM MgCl 2); the centrifugations were done at 3,000 g. Dried beads were sent for analysis at the Protein Analysis Facility platform (University of Lausanne).
Mass spectrometry analysis. The beads after GST pull down were washed three times with 1ϫ PBS and resuspended in 1ϫ SDS gel loading buffer to extract bound proteins. Samples were migrated on a 10% mini-polyacrylamide gel for ϳ2.0 cm and rapidly stained with Coomassie blue. Entire gel lanes were excised into seven regions from top to bottom and digested with trypsin (Promega) as described (59, 74) . Data-dependent liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis of extracted peptide mixtures after digestion was carried out on a hybrid linear trap LTQ-Orbitrap mass spectrometer (Thermo Fisher Scientific) interfaced to a nanocapillary HPLC equipped with a C 18 reverse-phase column eluted at 0.3 l/min. Collections of tandem mass spectra for database searching were generated from raw data and searched using Mascot (version 2.1.0, Matrix Science, London, UK) against the release 11.0 of the UNIPROT database, (SWISSPROTϩTrEMBL, www.uniprot.org) restricted to human taxonomy. The software Scaffold (version Scaffold-01_06_03, Proteome Software) was used to validate MS/MS-based peptide (minimum 95% probability) (27) and protein (minimum 99% probability) (41) identifications, perform data set alignment and subtraction, as well as parsimony analysis to discriminate homologous hits. Differentially detected proteins (absent in one sample or with varying numbers of spectra) were manually validated.
HEK293 Cell Experiments
cDNA constructs. Flag-tagged human NCC cloned into pCMV5 was provided by Prof. Dr. D. Alessi (MRC Protein Phosphorylation Unit, Univ. of Dundee, Dundee, UK) (50) . Wild-type NEDD4-2 and catalytically inactive NEDD4-2-C822S (NEDD4-2 CS) mutant constructs have been described previously (6) . These constructs were based on human NEDD4-2. The mouse Nedd4-2 construct was described previously (70) . Myc-tagged human WNK3 was subcloned into pcDNA3.1 (ϩ)/Zeo. The WNK3-PY mutant was generated using site-directed mutagenesis (51) .
HEK293 cell culture. HEK293 cells were cultured in DMEM (Invitrogen) with 10% FBS (Invitrogen) and incubated at 37°C/5% CO 2. The cells were transiently transfected in 10-cm dishes at 60% confluence using the calcium phosphate method (55) .
Immunoprecipitation from transfected HEK293 cells. Cells were washed twice with cold PBS (1ϫ) and lysed as described above for pull-down experiments. Cells were vortexed and then centrifuged for 15 min at 20,000 g at 4°C. Protein concentration on supernatants was quantified using the Bradford method. Immunoprecipitation was performed with a minimum of 500 g of protein. For WNK3, diluted lysates were incubated for 2 h at 4°C with anti c-Myc (Sigma) and then for 1 h with G protein-Sepharose (for monoclonal Ab; GE Healthcare). For NCC, lysates were incubated for 3 h with Flag M2-Agarose (Sigma). Samples were then centrifuged at 3,000 g and washed four times with 1 ml of washing buffer. Dried beads were resuspended in 40 l of 2ϫ sample buffer (5ϫ 1.47 M sucrose, 10% SDS, 5 mM EDTA, 300 mM Tris, pH 8.8, 0.25% bromophenol blue, and 130 mM dithiothreitol). Samples were heated at 95°C for 5 min and run on SDS-PAGE, transferred onto nitrocellulose membrane and analyzed by Western blotting. Kinase assay. S-tagged mouse Nedd4-2 was purified from transfected HEK293 cells and isolated with S-protein-agarose beads (Novagen). The kinase assay was performed directly on precipitated beads in kinase buffer (10 nM Tris·HCl, 150 mM NaCl, 10 mM MgCl 2, and 0,5 mM DTT) supplemented with 200 M cold ATP, 2.5 Ci 32 ATP, and 1 l of purified active WNK3 kinase (Millipore). The mix was incubated at 30°C for 15 min, and then the beads were washed three times with kinase buffer and resuspended in 2ϫ sample buffer. Samples were run on SDS-PAGE, transferred onto nitrocellulose membranes, and analyzed by autoradiography (13) .
Western blotting. Western blotting was carried out as described previously (55) . NCC was detected using an anti-Flag antibody (1:500, Sigma). Anti-NEDD4-2 (Abcam, Cambridge, UK) was diluted 1:500. Nedd4-2 was also detected using an S-tag antibody (Novagen). WNK3 was detected using an anti-c-Myc (1:500, Sigma) or an anti-WNK3 antibody provided by Prof. Alessi diluted 1:500 (69) . An anti-ubiquitin antibody was used to detect WNK3 ubiquitylation (Upstate). The anti-phospho-S222-NEDD4-2 (provided by Prof. Alessi) was diluted 1:600 (13) . The anti-phospho-S328-NEDD4-2 was diluted 1:500 (14) . Secondary antibodies coupled with HRP (GE Healthcare) were used 1:25,000, and Western blots were revealed with ECL reagents (GE Healthcare or Pierce, Rockford, IL).
Data Analysis
All results are presented as means Ϯ SE, and comparison between experimental groups was done using a nonpaired two-tailed Student's t-test. For NCC function, the results presented are based on a minimum of three independent experiments with 10 oocytes/group in each experiment. The significance of the difference between groups was evaluated with one-way ANOVA followed by a nonpaired two-tailed Student's t-test with Bonferroni's correction. In fold-activation analysis, control group mean uptake was normalized to a value of 1, and all other groups were then compared with the control group.
RESULTS
WNK3 Interacts with NEDD4-2 in a PY-Independent Manner
Using the X. laevis oocyte expression system, it was previously shown that WNK3 is a positive regulator of NCC (18, 51, 79) , while WNK4 is an inhibitor of the cotransporter (19, 76, 78) . Chimeric proteins, constructed by swapping the aminoand carboxyl-terminal domains of WNK3 and WNK4, suggested that the WNK3 activation and WNK4 inhibition of NCC properties reside on the amino-terminal domain sequences of the kinases (57) . To identify novel proteins involved in the WNK3-NCC and WNK4-NCC pathways, we generated GST fusion proteins of the amino-terminal domains of WNK3 and WNK4. GST pull-down assays were carried out, and interacting proteins were identified by LC-MS/MS analysis, as de- scribed in MATERIALS AND METHODS. This revealed among the pulled down peptides two sequences that correspond to NEDD4-2 ( Table 1 ), indicating that NEDD4-2 interacts with the amino-terminal domain of WNK3. As shown by pull-down assays in Fig. 1A , NEDD4-2 is specifically interacting with WNK3, but not WNK4. To confirm the interaction between full-length proteins, HEK293 cells were transfected with the c-Myc-tagged WNK3, NEDD4-2, or both. Coimmunoprecipitation of c-Myc-WNK3 and NEDD4-2 demonstrated that both proteins are part of the same complex (Fig. 1B) . In these experiments, we observed that the inactive NEDD4-2-CS mutant is less efficiently coimmunoprecipitated with WNK3 than wild-type NEDD4-2. At this point, we can only speculate about the reason behind this. It may suggest that WNK3 also interacts with ubiquitin, forming a thioester with the catalytic cysteine on NEDD4-2, consequently increasing its affinity (24) . NEDD4-2 is known to interact with proteins that contain a PY motif (PPxY), where P is a proline, X any amino acid, and Y a tyrosine (2, 23, 61) . WNK3 lacks the classic PPxY motif; however, a "PY-like" motif was found at position 347-348 (PY). Even though the PY-like motif was not located in the NH 2 -terminal domain that was shown to interact with NEDD4-2 in Fig. 1 , we decided to analyze the possibility that the presence of the PY-like motif identified in WNK3 is also involved in WNK3-NEDD4-2 interaction. Single-point mutagenesis was used to eliminate the PY-like motif in WNK3, by substituting the proline with an alanine residue (WNK3-P347A mutant). Then, c-Myc-WNK3, c-Myc-WNK3-P347A, and NEDD4-2 were transfected into HEK293 cells, and proteins were immunoprecipitated using an anti-c-Myc antibody. We observed that NEDD4-2 coimmunoprecipitated similarly with both WNK3 and WNK3-P347A (Fig.  1C, lanes 5 and 6) , suggesting a PY-motif-independent interaction between WNK3 and NEDD4-2.
WNK3 Reverses NEDD4-2-Mediated Inhibition of NCC
NEDD4-2 was previously identified as a regulator of NCC (3) . In light of the interaction between NEDD4-2 and WNK3, we tested the effect of WNK3 and NEDD4-2 on NCC by measuring the thiazide-sensitive 22 Na ϩ tracer uptake in X. laevis oocytes injected with NCC cRNA alone or coinjected with WNK3 and/or NEDD4-2 cRNA (Fig. 2A) . Oocytes injected with NCC cRNA alone had a mean uptake of 2,259 Ϯ 200 pmol·oocyte Ϫ1 ·h Ϫ1 that was sensitive to thiazides. In accordance with previous observations, when NCC was coinjected with WNK3 cRNA, the Na ϩ uptake increased to 6,572 Ϯ 603 pmol·oocyte Ϫ1 ·h Ϫ1 (P Ͻ 0.01 vs. NCC) (51) and, when coinjected with NEDD4-2 cRNA, uptake decreased to 954 Ϯ 89 pmol·oocyte Ϫ1 ·h Ϫ1 (P Ͻ 0.01 vs. NCC) (3). The addition of WNK3 cRNA to the NCCand NEDD4-2-coinjected oocytes did not just fully reverse the inhibitory effect of NEDD4-2 (P Ͻ 0.01 vs. NCC ϩ NEDD4-2) but was able to increase the Na ϩ uptake to 4,256 Ϯ 314 pmol·oocyte Ϫ1 ·h Ϫ1 (P Ͻ 0.01 vs. NCC). The WNK3-induced fold-activation of NCC in the presence of NEDD4-2 was significantly higher than in the absence of the ligase. WNK3 generates a 3.4-fold increase in NCC activity, whereas, in the presence of NEDD4-2, WNK3 increases NCC activity by 4.8-fold (P Ͻ 0.05) (Fig. 2B) . This observation suggests that WNK3 is not only activating the NCC that had not been inhibited by NEDD4-2, but it probably is also precluding the inhibitory effect of NEDD4-2 on NCC. We then evaluated the effect of WNK3 on NCC-NEDD4-2 interaction. We had previously observed that NEDD4-2 and NCC interact and that SGK1 is capable of abrogating this interaction in a kinase-dependent fashion (3). To test whether WNK3 has a similar effect, HEK293 cells were transfected with Flag-tagged NCC and NEDD4-2, with or without WNK3, after which a Flag tag immunoprecipitation was carried out (Fig. 3) . The interaction of NCC and NEDD4-2 in the presence of WNK3 was maintained (lane 7).
NEDD4-2 Does Not Ubiquitylate WNK3
Given that NEDD4-2 is an E3 ubiquitin-protein ligase (66), we tested whether NEDD4-2 could be regulating WNK3 through ubiquitylation. HEK293 cells were transfected with Myc-tagged WNK3, combined with wild-type or catalytically inactive NEDD4-2, as indicated in Fig. 4 . Immunoprecipitation with anti-c-Myc antibodies revealed no significant difference in the ubiquitylation of WNK3 between groups, suggesting that the ubiquitylation of WNK3 is not modified by NEDD4-2.
Together with the functional uptake experiments, our data suggest that rather than NEDD4-2 regulating WNK3, WNK3 is in fact regulating the activity of NEDD4-2.
WNK3 Does Not Phosphorylate NEDD4-2 On Serine 222 or 328
SGK1 is known to inhibit the NEDD4-2 negative effect on ENaC and NCC by phosphorylating NEDD4-2 on serine residue 328 (numbering for mouse NEDD4-2) and to a lesser extent serine residue 222 (10, 63, 64) . To test whether WNK3 phosphorylates serine 222 and/or serine 328, thus inhibiting NEDD4-2, HEK293 cells were transfected with NEDD4-2 or SGK1 in the presence or absence of WNK3 (Fig. 5) . Phosphorylation of serine 222 and serine 328 increased in the presence of SGK1 (lane 6). This effect was not mimicked by the addition of WNK3, as there was no difference in the phosphorylation of serine 222 (Fig. 5B ) or serine 328 (Fig. 5C ) alone or in the presence of WNK3 (lane 5), suggesting that if WNK3 regulates NEDD4-2, the mechanism is different for SGK1 since phosphorylation of serine 222 or 328 is not implicated.
WNK3 Directly Interferes With NEDD4-2-Mediated Inhibition of NCC
Because we observed no increase in phosphorylation of S222 or S328 of NEDD4-2 in the presence of WNK3, we next tested the effect of WNK3 on the NEDD4-2-dependent inhibition of NCC. For this, we used a NEDD4-2 double mutant S222A/S328A (NEDD4-2-DMA), in which both phosphorylation sites have been eliminated. We previously showed that NEDD4-2's inhibitory effect on NCC is enhanced by elimination of these two serine residues on NEDD4-2 and that NEDD4-2-DMA becomes insensitive to SGK1, implicating the residues S222 and S328 in the regulation of NCC by the SGK1-NEDD4-2 pathway (3). In the present study, X. laevis oocytes were injected with cRNA encoding NCC, NCCϩwild-type NEDD4-2, or NCCϩNEDD4-2-DMA in the presence or absence of WNK3. NCC activity was assessed by measuring 22 Na ϩ uptake in the presence or absence of thiazides, 3 days after oocytes were injected. Similar to our previous observations, inhibition of NCC by NEDD4-2-DMA was shown to be more efficient than that of NEDD4-2. NEDD4-2-DMA remarkably reduced NCC functional activity from 2,666 Ϯ 328 to 197 Ϯ 138 pmol·oocyte Ϫ1 ·h Ϫ1 (P Ͻ 0.10 Ϫ9 ) (Fig.  6A) . Interestingly, in contrast to SGK1, which does not have any effect on NEDD4-2-DMA-mediated inhibition of NCC (3), the addition of WNK3 abolished the effect of NEDD4-2-DMA on NCC compared with NCC alone. The difference in fold-activation of NCC induced by WNK3 observed in the absence or presence of NEDD4-2-DMA corroborates that WNK3 abrogates the NEDD4-2-mediated inhibition of the cotransporter (Fig. 6B ). In the presence of NEDD4-2-DMA, fold-activation of NCC by WNK3 (17.7 Ϯ 2.2) became significantly higher compared with NCC and WNK3 in the absence of NEDD4-2 (3.25 Ϯ 0.238) (P Ͻ 0.0001). These observations suggest that WNK3 had both the ability to simultaneously activate NCC (51) and to inhibit NEDD4-2, through a mechanism that differs from that of SGK1 since phosphorylation of serine residues 222 and 328 is not implicated.
It has been recently observed that WNK3-mediated activation of NCC is a SPAK-dependent process that requires the interaction between WNK3 and SPAK via a SPAKbinding site, 241 RFxV, within WNK3 (45) . Indeed, a mutant lacking the SPAK binding site, WNK3-F242A, is no longer able to increase the activity of NCC (45) . Thus, to distinguish between the two proposed NCC-regulatory mechanisms, namely 1) WNK3-mediated activation of NCC (SPAK-dependent) or 2) WNK3-mediated inhibition of NEDD4-2 (SPAK-independent), we took advantage of the WNK3-F242A mutant. X. laevis oocytes were injected with cRNA encoding NCC in the presence or absence of NEDD4-2, wild-type WNK3, and/or the mutant WNK3-F242A. As shown in Fig. 7A and according to our previous observations, wild-type WNK3 was able to activate NCC in the absence or presence of NEDD4-2. As previously reported, WNK3-F242A had no effect on NCC functional activity (45). However, it was able to fully recover the NEDD4-2-mediated inhibition of NCC, without further activation of NCC. This result strongly suggests that WNK3 prevents NEDD4-2-mediated inhibition of NCC, independently of its capacity to activate the co-transporter. Figure 7 , B and C, shows that the functional observations were mimicked by changes in the membrane protein level. Figure 7B shows a representative Western blot of total and membrane fraction proteins extracted from X. laevis oocytes previously injected with combinations of NCC, Nedd4-2, wild-type WNK3, or WNK3-F242A cRNA, and Fig. 7C depicts the compiled analysis from three different experiments. We corroborated that there was no change in NCC expression level when total proteins were analyzed, in the presence or absence of NEDD4-2, WNK3, or WNK3-F242A. In the membrane fraction, however, NEDD4-2 decreased NCC expression, and both WNK3 and WNK3-F242A were able to recover the membrane NCC expression level, further demonstrating that WNK3 is able to inhibit NEDD4-2, independently of its ability to increase NCC functional activity.
WNK3 Phosphorylates NEDD4-2 In Vitro
Our observations suggest that, in addition to activation of NCC, WNK3 prevents the NEDD4-2-induced decrease in NCC expression in the plasma membrane and thus its functional activity, by a mechanism independent of the phosphorylation of serine residues 222 and 328. Thus we surmised that WNK3 may phosphorylate NEDD4-2 on other residues. To test whether WNK3 is able to directly phosphorylate NEDD4-2, we performed an in vitro kinase assay, using purified S-tagged NEDD4-2 and recombinant WNK3. As shown in Fig. 7D , the addition of WNK3 induced the phosphorylation of NEDD4-2. Hence WNK3 has the capability to directly phosphorylate NEDD4-2.
DISCUSSION
Renal NCC activity is fundamental for several important physiological properties of the kidney, including 1) determination of body salt content, which in turn is critical to define the intravascular filling pressure and thus, arterial blood pressure; (2) potassium excretion capability, because salt reabsorption in the DCT is critical in determining distal sodium delivery to the collecting duct, which is required for potassium secretion; 3) hydrogen secretion capacity, because this in turn depends, at least in part, on potassium concentration in the collecting duct fluid; and 4) calcium metabolism, as salt and calcium reabsorption by the DCT operate in opposite fashion, i.e., the higher the salt, the lower the calcium reabsorption. Thus regulation of NCC is a multifaceted and complex task through which the cotransporter's activity must be modulated to achieve different, yet simultaneous functions.
The WNK family of serine/threonine kinases, in conjunction with the downstream SPAK or OSR1 serine/threonine kinases, plays a key role in the regulation of the NCC (16, 49) . The WNK kinase family is composed of four members, WNK1-WNK4. Mutations in the genes of two members (WNK1 and WNK4) cause PHAII, which is mainly due to hyperactivation of NCC through mechanisms that are still unresolved. The effects of all members of the WNK kinase family on NCC and other members of the electroneutral cation-coupled chloride cotransporter family SLC12 to which NCC belongs have been extensively studied using in vitro and in vivo models (34) . WNK1 is purported to be an indirect activator of NCC, which exerts its effect by preventing the inhibitory effect of WNK4 on NCC (5, 80) . Whereas WNK2 is not expressed in the kidney (52), WNK3 stimulates NCC activity by a SPAK-dependent mechanism (45, 51) . WNK4 is an inhibitor of NCC (76) , which becomes an activator in the presence of angiotensin II, or when harboring PHAII mutations, through a SPAK-dependent . WNK3 is able to recover the NEDD4-2 S222A,S328A-mediated inhibition of NCC. A: thiazide-sensitive 22 Na ϩ uptake in the absence (open bars) or presence of WNK3 (filled bars) in X. laevis oocytes injected with different combinations of NCC, WNK3, NEDD4-2 (N4-2), or NEDD4-2 S222A,S328A (N4DMA) cRNA, as stated. WNK3 was able to fully reverse both the N4-2 and N4DMA-mediated inhibition of NCC. B: fold-activity in the presence or absence of WNK3 was compared between each group. The fold-activation of WNK3 in the presence of NEDD4-2 and NEDD4-2-DMA was greater than that of NCC alone. **P Ͻ 0.001 vs. NCC. mechanism (56) . Additionally, WNK4 has been shown to modify NCC total protein quantity by increasing the lysosomal degradation of NCC (8, 67, 82) . Interaction between WNKs can potentiate or prevent the effect of one over another (68, 69, 79) . This observation is significant given the mild renal phenotypes reported in two recently described WNK3 knockout mouse models, which suggest that the overexpression of WNK1 and/or WNK4 is potentially offsetting the lack of WNK3 in the kidney (36) (43) .
Another novel NCC-regulating network is composed by the ubiquitin system. Recently it was shown that NCC surface expression is modulated by ubiquitylation induced by the HECT-E3 ubiquitin-protein ligase NEDD4-2, also known to regulate ENaC, and that the effect of NEDD4-2 on NCC can be prevented through SGK1 phosphorylation of NEDD4-2, providing a pathway for the regulation of NCC by aldosterone (3). Moreover, in vivo evidence published by Ronzaud et al. (54) showed that the inducible, nephron-specific knockdown of NEDD4-2 generates salt-dependent hypertension and increased abundance of total and phosphorylated NCC. Alongside the role of NEDD4-2, it was also shown that RasGRP1 stimulation decreased NCC expression in the plasma membrane through increased ubiquitylation of NCC (29) . Additionally, mutations in the genes encoding cullin 3 and Kelch 3 (forming a RING-E3 ubiquitin-protein ligase) cause a PHAII phenotype that seems to be more severe than the PHAII phenotype caused by WNKs, because the clinical picture is present at a younger age of life (7, 32) . It was proposed that disruption of this regulatory mechanism on NCC could be behind PHAII in these patients (32) . For the above reasons, it would not be surprising that the regulation of NCC incorporates interaction between phosphorylating kinases and the ubiquitylating ligases. Our data provide evidence to support such a novel mechanism for NCC regulation.
WNK3 was initially reported to activate the Na ϩ -Cl Ϫ -coupled members of the SLC12 family of solute carriers (51), while inhibiting the K ϩ -Cl Ϫ -coupled members (11) . Because of the different effects of WNK3 and WNK4 on NCC in the same expression system, we constructed chimeras between both WNKs and observed that sequences within the aminoterminal domain could be implicated in defining the type of effect on NCC (57) and thus initially searched for WNK3 or WNK4 amino-terminal domain potential partners. The pulldown assay with GST fusion proteins built with the aminoterminal domain of WNK3 suggested that NEDD4-2 could be interacting with WNK3 and could potentially be involved in the regulation of NCC, not only by phosphorylating the cotransporter, but also by preventing its ubiquitylation and removal from the plasma membrane. As discussed above, we have shown that NEDD4-2 is indeed regulating NCC expression levels (3). Our GST pull-down assay revealed that NEDD4 -2 interacts with the N-terminus of WNK3, but not WNK4 (Fig. 1A) and that this occurs not only with the fusion protein, but also with full-length WNK3 (Fig. 1B) . At the functional level, WNK3 was fully capable of reverting the NEDD4-2-mediated inhibition of NCC (Fig. 2) . The lack of a disruption of the interaction between NEDD4-2 and NCC in the presence of WNK3 (Fig. 3) , and the absence of WNK3 ubiquitylation in the presence of NEDD4-2 (Fig. 4) , suggested that WNK3 regulates NEDD4-2, and not the other way around. In addition, these observations also suggested that the effect of WNK3 on NCC-NEDD4-2 is different from that of SGK1 (3). It is known that SGK1 modulates the effects of NEDD4-2 on NCC and ENaC by phosphorylating serine residues 222 and 328 of NEDD4-2 (3, 10) . In this regard, we observed that phosphorylation of NEDD4-2 on serine 328 and on serine 222 did not vary in the presence or absence of WNK3 (Fig. 5) , supporting that SGK1 and WNK3 exert an effect on NEDD4-2 through different mechanisms. In addition, we noticed that, while the double mutant NEDD4-2, in which serine residues 222 and 328 was eliminated, was insensitive to SGK1 (3), it was still fully responsive to WNK3's inhibitory effect (Fig. 6) . Finally, distinguishing between the WNK3-activating properties on NCC and the WNK3-inhibitory effect on NEDD4-2 was possible because the former is SPAK dependent, while the latter is not. The WNK3-F242A mutant, in which one of the SPAK kinase binding site was eliminated (45) , lost its ability to increase the activity of NCC but was still able to completely prevent the NEDD4-2 inhibition of NCC (Fig.  7) . This suggests that WNK3 acts via two different mechanisms: 1) SPAK/OSR1-dependent activation of NCC or 2) inhibition of NEDD4-2-dependent reduction of plasma membrane expression.
The exact mechanism through which WNK3 is capable of inhibiting NEDD4-2, however, is still unclear. The increased total protein phosphorylation of NEDD4-2 in the presence of WNK3 suggests that WNK3 phosphorylates NEDD4-2 in residues other than S328 and S222. Other groups have shown that there are alternate phosphorylation sites on NEDD4-2 that are key in regulating the activity of NEDD4-2 (9, 63). Consequently, this raises the exciting possibility of a differential regulation of NEDD4-2 by multiple kinases and with differential effects on downstream targets. Nonetheless, further work is required to elucidate the specific mechanism through which phosphorylation is taking place.
In conclusion, we propose that WNK3 regulates NCC, at least through two different pathways (Fig. 8) . On the one hand, through a SPAK/OSR-dependent mechanism, WNK3 increases the phosphorylation of NCC in the N-terminal threonine residues, known to be associated with its activation (44, 45) . On the other hand, WNK3 inhibits the NEDD4-2 mediated degradation of NCC at the plasma membrane. Interestingly, the mechanism by which SGK1 and WNK3 prevent the effect of NEDD4-2 on NCC is apparently different. SGK1 inhibition of NEDD4-2 requires the presence of serine residues 222 and 328, while the effect of WNK3 occurs in the absence of these serines, and thus likely is due to phosphorylation of NEDD4-2 on other, unknown sites. Hence, these observations provide an opportunity for fine regulation of the cotransporter. Our previous work with the K ϩ -Cl Ϫ cotransporters suggests that WNK3 could be also implicated in modulating the activity of protein phosphatases toward these cotransporters (11) . Because NCC activity is associated with its phosphorylation (44) and activity of protein phosphatases has been proposed to affect the cotransporter (17, 47) , it is possible that regulation of protein phosphatases by WNK3 could be a third mechanism for modulation of NCC that will need to be addressed. 
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